CONTEXT: The treatment of pain in patients with substance use disorders creates tensions for clinicians between undertreating pain and enabling opioid analgesic misuse. OBJECTIVES: To characterize prevalence and factors associated with aberrant opioid analgesic behaviors in a cohort of HIV-infected individuals who are at high risk for opioid analgesic misuse. METHODS: We assessed pain and substance use disorders in a cross-sectional study that enrolled 296 participants from the Research on Access to Care in the Homeless cohort, a community-based sample of indigent HIV-infected adults. We measured aberrant opioid behaviors, defined as major or minor depending on level of risk of harm to patients, using Audio Computer-Assisted Self-Interview technology. RESULTS: Most participants (91.2%) reported pain in the week before interview, with the majority of these experiencing severe pain (53.7%). More than two-thirds (69.2%) of the participants met criteria for a lifetime history of cocaine, amphetamine, or heroin/opioid use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). More than one-third of the sample (37.4%) had a history of aberrant opioid behavior within 90 days of interview. One-fifth (18.5%) had a history of "major" aberrant behaviors. CONCLUSION: In this high-risk population, severe pain is common and aberrant opioid behaviors are prevalent but not universal. As recommended by American Pain Society and American Academy of Pain Medicine guidelines, when prescribing opioid analgesics, clinicians must consider variation in the severity of aberrant behaviors, particularly aberrant behaviors that may represent undertreatment of pain.
CONTEXT: The treatment of pain in patients with substance use disorders creates tensions for clinicians between undertreating pain and enabling opioid analgesic misuse. OBJECTIVES: To characterize prevalence and factors associated with aberrant opioid analgesic behaviors in a cohort of HIV-infected individuals who are at high risk for opioid analgesic misuse. METHODS: We assessed pain and substance use disorders in a cross-sectional study that enrolled 296 participants from the Research on Access to Care in the Homeless cohort, a community-based sample of indigent HIV-infected adults. We measured aberrant opioid behaviors, defined as major or minor depending on level of risk of harm to patients, using Audio Computer-Assisted Self-Interview technology. RESULTS: Most participants (91.2%) reported pain in the week before interview, with the majority of these experiencing severe pain (53.7%). More than two-thirds (69.2%) of the participants met criteria for a lifetime history of cocaine, amphetamine, or heroin/opioid use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). More than one-third of the sample (37.4%) had a history of aberrant opioid behavior within 90 days of interview. One-fifth (18.5%) had a history of "major" aberrant behaviors. CONCLUSION: In this high-risk population, severe pain is common and aberrant opioid behaviors are prevalent but not universal. As recommended by American Pain Society and American Academy of Pain Medicine guidelines, when prescribing opioid analgesics, clinicians must consider variation in the severity of aberrant behaviors, particularly aberrant behaviors that may represent undertreatment of pain.
Authors: Edward Michna; Edgar L Ross; Wilfred L Hynes; Srdjan S Nedeljkovic; Sharonah Soumekh; David Janfaza; Diane Palombi; Robert N Jamison Journal: J Pain Symptom Manage Date: 2004-09 Impact factor: 3.612
Authors: Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski Journal: J Pain Date: 2009-02 Impact factor: 5.820
Authors: Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison Journal: Pain Date: 2007-05-09 Impact factor: 6.961
Authors: Laura L Adams; Robert J Gatchel; Richard C Robinson; Peter Polatin; Noor Gajraj; Martin Deschner; Carl Noe Journal: J Pain Symptom Manage Date: 2004-05 Impact factor: 3.612
Authors: Julie R Gaither; Joseph L Goulet; William C Becker; Stephen Crystal; E Jennifer Edelman; Kirsha Gordon; Robert D Kerns; David Rimland; Melissa Skanderson; Daniel F Weisberg; Amy C Justice; David A Fiellin Journal: J Pain Date: 2014-08-23 Impact factor: 5.820
Authors: Lisa R LaRowe; Lauren N Chilcott; Michael J Zvolensky; Peter A Vanable; Kelley Flood; Joseph W Ditre Journal: Subst Use Misuse Date: 2018-04-30 Impact factor: 2.164
Authors: Shannon M Smith; Florence Paillard; Andrew McKeown; Laurie B Burke; Robert R Edwards; Nathaniel P Katz; Elektra J Papadopoulos; Bob A Rappaport; Ashley Slagle; Eric C Strain; Ajay D Wasan; Dennis C Turk; Robert H Dworkin Journal: J Pain Date: 2015-02-04 Impact factor: 5.820
Authors: Benjamin J Oldfield; Nicolas Muñoz; Mark P McGovern; Melissa Funaro; Merceditas Villanueva; Jeanette M Tetrault; E Jennifer Edelman Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Cynthia I Campbell; Andrea H Kline-Simon; Michael Von Korff; Kathleen W Saunders; Constance Weisner Journal: Subst Use Misuse Date: 2017-03-27 Impact factor: 2.164
Authors: Celia C Y Wong; Daniel J Paulus; Chad Lemaire; Amy Leonard; Carla Sharp; Clayton Neighbors; Charles P Brandt; Qian Lu; Michael J Zvolensky Journal: J HIV AIDS Soc Serv Date: 2017-11-30
Authors: Brian A Perry; Andrew O Westfall; Elizabeth Molony; Rodney Tucker; Christine Ritchie; Michael S Saag; Michael J Mugavero; Jessica S Merlin Journal: J Palliat Med Date: 2013-03-11 Impact factor: 2.947
Authors: E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin Journal: HIV Med Date: 2016-11 Impact factor: 3.180